Search results for "From ACP Journal Club"
Review: Adding a DPP-4 inhibitor to an SGLT-2 inhibitor reduces genital, but not genitourinary, tract infections
The authors of an accompanying ACP Journal Club commentary noted that although the risk for bias in the five reviewed studies was reportedly low, the results were imprecise and inconsistent, leaving little confidence in the evidence of an apparent reduction in infection risk with dipeptidyl peptidase-4 (DPP-4) inhibitors.
https://diabetes.acponline.org/archives/2018/04/13/7.htm
13 Apr 2018
KDIGO made 12 recommendations for managing diabetes with CKD
The kidney group's guideline supports metformin and sodium–glucose cotransporter-2 inhibitors as first-line therapies for patients with chronic kidney disease (CKD) based on consistent trial data showing their effectiveness, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2021/03/12/6.htm
12 Mar 2021
Some glucose-lowering drugs reduce risk for major adverse cardiac events
An umbrella review found cardiovascular benefits from sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, but an ACP Journal Club commentary cautioned that included patients were on a wide array of background treatments.
https://diabetes.acponline.org/archives/2020/08/14/7.htm
14 Aug 2020
Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers
An industry-funded randomized trial showed that topical wound oxygen therapy is efficacious, but more data on effectiveness, outcomes, and cost are needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/04/10/6.htm
10 Apr 2020
In type 2 diabetes with periodontitis, intensive periodontitis treatment improved glycemic control at 1 year
Putting these findings into practice may require incorporating dental professionals into diabetes care teams and training clinicians who treat patients with diabetes to recognize and assess periodontal disease and make appropriate referrals, the ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2019/05/10/8.htm
10 May 2019
Glargine and liraglutide improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin, while liraglutide reduced CV events vs. glargine, glimepiride, or sitagliptin
Although microvascular complications and death were not materially different among the four treatment groups in a recent trial, the results do allow inferences about the role of sulfonylureas and dipeptidyl peptidase-4 inhibitors in practice, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/01/13/8.htm
13 Jan 2023
Some glucose-lowering drugs reduce HbA1c more than others
A recent meta-analysis supports the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in patients with diabetes and elevated cardiovascular risk, but cost remains a barrier, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/8.htm
11 Dec 2020
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
A cohort study's finding of increased risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT2) inhibitors is relevant to clinical decision making, but not definitive given the limitations of observational research, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/01/08/6.htm
8 Jan 2021
In diabetes, some statins reduce non–HDL-C better than others vs. placebo
A review reaffirmed well-known information about the potency of commonly prescribed statins and suggested that non–high-density lipoprotein cholesterol (HDL-C) may be a better measure of cardiovascular risk than low-density lipoprotein cholesterol in patients on statins, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/08/12/6.htm
12 Aug 2022
In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia
An ACP Journal Club commentary pointed out that use of once-weekly insulin for patients with type 2 diabetes will require more cautious dose-titration algorithms and less stringent glycemic targets to avoid hypoglycemia.
https://diabetes.acponline.org/archives/2021/03/12/7.htm
12 Mar 2021